[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
Identifieur interne : 001259 ( Istex/Corpus ); précédent : 001258; suivant : 001260[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
Auteurs : Belinda Bokobza ; Merle Ruberg ; Bernard Scatton ; France Javoy-Agid ; Yves AgidSource :
- European Journal of Pharmacology [ 0014-2999 ] ; 1984.
Abstract
The density of D2-type dopamine receptors, measured by the binding of [3H]spiperone was normal in the substantia nigra, caudate nucleus and nucleus accumbens of Parkinsonian subjects and above control levels in the putamen, in spite of massive lesions of the dopaminergic neurons. Dopamine levels were reduced in the putamen, caudate nucleus, and nucleus accumbens by 97, 85 and 68%, respectively and by 78 and 93% in the pars compacta and pars reticulata of the substantia nigra. HVA levels were much less affected suggesting that increased activity remaining dopaminergic neurons compensated to some extent for the lesions. Neuroleptic treatment and the presence of dementia in the Parkinsonian subjects affected [3H]spiperone binding and dopamine concentrations. Dopamine and HVA levels in the striatum of subjects with supranuclear palsy indicate that the nigrostriatal system was lesioned to the same degree in this disease as in idiopathic Parkinsonism, but spiperone binding was reduced by half in all the structures studies.
Url:
DOI: 10.1016/0014-2999(84)90238-3
Links to Exploration step
ISTEX:725D196A3549D7EF909C41B41560C57B14E8C280Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</title><author><name sortKey="Bokobza, Belinda" sort="Bokobza, Belinda" uniqKey="Bokobza B" first="Belinda" last="Bokobza">Belinda Bokobza</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation></author><author><name sortKey="Ruberg, Merle" sort="Ruberg, Merle" uniqKey="Ruberg M" first="Merle" last="Ruberg">Merle Ruberg</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation></author><author><name sortKey="Scatton, Bernard" sort="Scatton, Bernard" uniqKey="Scatton B" first="Bernard" last="Scatton">Bernard Scatton</name><affiliation><mods:affiliation>Synthélabo-LERS, Départements de Biologie, 31 Av P. Vaillant-Couturier, 92220 Bagneux, France</mods:affiliation></affiliation></author><author><name sortKey="Javoy Agid, France" sort="Javoy Agid, France" uniqKey="Javoy Agid F" first="France" last="Javoy-Agid">France Javoy-Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation><affiliation><mods:affiliation>To whom all correspondence should be addressed.</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:725D196A3549D7EF909C41B41560C57B14E8C280</idno><date when="1984" year="1984">1984</date><idno type="doi">10.1016/0014-2999(84)90238-3</idno><idno type="url">https://api.istex.fr/document/725D196A3549D7EF909C41B41560C57B14E8C280/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001259</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001259</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</title><author><name sortKey="Bokobza, Belinda" sort="Bokobza, Belinda" uniqKey="Bokobza B" first="Belinda" last="Bokobza">Belinda Bokobza</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation></author><author><name sortKey="Ruberg, Merle" sort="Ruberg, Merle" uniqKey="Ruberg M" first="Merle" last="Ruberg">Merle Ruberg</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation></author><author><name sortKey="Scatton, Bernard" sort="Scatton, Bernard" uniqKey="Scatton B" first="Bernard" last="Scatton">Bernard Scatton</name><affiliation><mods:affiliation>Synthélabo-LERS, Départements de Biologie, 31 Av P. Vaillant-Couturier, 92220 Bagneux, France</mods:affiliation></affiliation></author><author><name sortKey="Javoy Agid, France" sort="Javoy Agid, France" uniqKey="Javoy Agid F" first="France" last="Javoy-Agid">France Javoy-Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation><affiliation><mods:affiliation>To whom all correspondence should be addressed.</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Pharmacology</title><title level="j" type="abbrev">EJP</title><idno type="ISSN">0014-2999</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1984">1984</date><biblScope unit="volume">99</biblScope><biblScope unit="issue">2–3</biblScope><biblScope unit="page" from="167">167</biblScope><biblScope unit="page" to="175">175</biblScope></imprint><idno type="ISSN">0014-2999</idno></series><idno type="istex">725D196A3549D7EF909C41B41560C57B14E8C280</idno><idno type="DOI">10.1016/0014-2999(84)90238-3</idno><idno type="PII">0014-2999(84)90238-3</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-2999</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The density of D2-type dopamine receptors, measured by the binding of [3H]spiperone was normal in the substantia nigra, caudate nucleus and nucleus accumbens of Parkinsonian subjects and above control levels in the putamen, in spite of massive lesions of the dopaminergic neurons. Dopamine levels were reduced in the putamen, caudate nucleus, and nucleus accumbens by 97, 85 and 68%, respectively and by 78 and 93% in the pars compacta and pars reticulata of the substantia nigra. HVA levels were much less affected suggesting that increased activity remaining dopaminergic neurons compensated to some extent for the lesions. Neuroleptic treatment and the presence of dementia in the Parkinsonian subjects affected [3H]spiperone binding and dopamine concentrations. Dopamine and HVA levels in the striatum of subjects with supranuclear palsy indicate that the nigrostriatal system was lesioned to the same degree in this disease as in idiopathic Parkinsonism, but spiperone binding was reduced by half in all the structures studies.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Belinda Bokobza</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</json:string></affiliations></json:item><json:item><name>Merle Ruberg</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</json:string></affiliations></json:item><json:item><name>Bernard Scatton</name><affiliations><json:string>Synthélabo-LERS, Départements de Biologie, 31 Av P. Vaillant-Couturier, 92220 Bagneux, France</json:string></affiliations></json:item><json:item><name>France Javoy-Agid</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</json:string><json:string>To whom all correspondence should be addressed.</json:string></affiliations></json:item><json:item><name>Yves Agid</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Supranuclear palsy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine receptor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Homovanillic acid</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>The density of D2-type dopamine receptors, measured by the binding of [3H]spiperone was normal in the substantia nigra, caudate nucleus and nucleus accumbens of Parkinsonian subjects and above control levels in the putamen, in spite of massive lesions of the dopaminergic neurons. Dopamine levels were reduced in the putamen, caudate nucleus, and nucleus accumbens by 97, 85 and 68%, respectively and by 78 and 93% in the pars compacta and pars reticulata of the substantia nigra. HVA levels were much less affected suggesting that increased activity remaining dopaminergic neurons compensated to some extent for the lesions. Neuroleptic treatment and the presence of dementia in the Parkinsonian subjects affected [3H]spiperone binding and dopamine concentrations. Dopamine and HVA levels in the striatum of subjects with supranuclear palsy indicate that the nigrostriatal system was lesioned to the same degree in this disease as in idiopathic Parkinsonism, but spiperone binding was reduced by half in all the structures studies.</abstract><qualityIndicators><score>6.675</score><pdfVersion>1.2</pdfVersion><pdfPageSize>591 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1032</abstractCharCount><pdfWordCount>4815</pdfWordCount><pdfCharCount>25967</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>155</abstractWordCount></qualityIndicators><title>[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</title><pii><json:string>0014-2999(84)90238-3</json:string></pii><refBibs><json:item><author><json:item><name>Y. Agid</name></json:item><json:item><name>P. Guyenet</name></json:item><json:item><name>J. Glowinski</name></json:item><json:item><name>J.C. Beaujouan</name></json:item><json:item><name>F. Javoy</name></json:item></author><host><volume>86</volume><pages><first>488</first></pages><author></author><title>Brain Res.</title></host><title>Inhibitory influence of the nigrostriatal dopamine system on the striatal cholinergic neurons in the rat</title></json:item><json:item><author><json:item><name>A. Cheramy</name></json:item><json:item><name>V. Laviel</name></json:item><json:item><name>J. Glowinski</name></json:item></author><host><volume>289</volume><pages><first>537</first></pages><author></author><title>Nature</title></host><title>Dendritic release of dopamine in the substantia nigra</title></json:item><json:item><author><json:item><name>B. Dubois</name></json:item><json:item><name>M. Ruberg</name></json:item><json:item><name>F. Javoy-Agid</name></json:item><json:item><name>Y. Agid</name></json:item></author><host><volume>288</volume><pages><first>213</first></pages><author></author><title>Brain Res.</title></host><title>A subcortico-cortical cholinergic system is affected in Parkinson's disease</title></json:item><json:item><author><json:item><name>S. Fahn</name></json:item><json:item><name>L.R. Libsch</name></json:item><json:item><name>R.W. Cutler</name></json:item></author><host><volume>14</volume><pages><first>427</first></pages><author></author><title>J. Neurol. Sci.</title></host><title>Monoamines in the human neostriatum: Topographic distribution in normals andin Parkinson's disease and their role in akinesia, rigidity, chorea and tremor</title></json:item><json:item><author><json:item><name>M.F. Giorguieff</name></json:item><json:item><name>M.L. LeFloc'h</name></json:item><json:item><name>J. Glowinski</name></json:item><json:item><name>M.J. Besson</name></json:item></author><host><volume>200</volume><pages><first>535</first></pages><author></author><title>J. Pharmacol. Exp. Ther.</title></host><title>Involvement of cholinergic presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of dopamine from striatal dopaminergic terminals in the rat</title></json:item><json:item><author><json:item><name>M. Hall</name></json:item><json:item><name>P. Jenner</name></json:item><json:item><name>E. Kelly</name></json:item><json:item><name>C.D. Marsden</name></json:item></author><host><author></author><title>Br. J. Pharmacol.</title></host><title>Differential anatomical location of [3H]N-n-propylnorapomorphine and [3H]spiperone binding sites in the striatum and substantia nigra of the</title></json:item><json:item><author><json:item><name>I. Helmreich</name></json:item><json:item><name>W. Reimann</name></json:item><json:item><name>G. Hertling</name></json:item><json:item><name>K. Starke</name></json:item></author><host><volume>7</volume><pages><first>1559</first></pages><author></author><title>Neuroscience</title></host><title>Are presynaptic dopamine autoreceptors and postsynaptic dopamine receptors in the rabbit pharmacologically different</title></json:item><json:item><author><json:item><name>P. Laduron</name></json:item><json:item><name>J.E. Leysen</name></json:item></author><host><volume>28</volume><pages><first>2161</first></pages><author></author><title>Biochem. Pharmacol.</title></host><title>Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity</title></json:item><json:item><author><json:item><name>T. Lee</name></json:item><json:item><name>P. Seeman</name></json:item><json:item><name>O. Hornykiewicz</name></json:item><json:item><name>J. Bilbao</name></json:item><json:item><name>W.W. Tourtellotte</name></json:item></author><host><volume>212</volume><pages><first>494</first></pages><author></author><title>Brain Res.</title></host><title>Parkinson's disease: low density and presynaptic location of D3 receptors</title></json:item><json:item><author><json:item><name>T. Lee</name></json:item><json:item><name>P. Seeman</name></json:item><json:item><name>A. Rajput</name></json:item><json:item><name>I.J. Farley</name></json:item><json:item><name> Hornykiewicz</name></json:item></author><host><volume>273</volume><pages><first>59</first></pages><author></author><title>Nature</title></host><title>Receptor basis for dopaminergic supersensitivity in Parkinson's disease</title></json:item><json:item><author><json:item><name>J. Lehmann</name></json:item><json:item><name>M. Briley</name></json:item><json:item><name>S.Z. Langer</name></json:item></author><host><volume>88</volume><pages><first>11</first></pages><author></author><title>European J. Pharmacol.</title></host><title>Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel receptor agonists</title></json:item><json:item><author><json:item><name>J. Lehmann</name></json:item><json:item><name>S.Z. Langer</name></json:item></author><host><volume>248</volume><pages><first>61</first></pages><author></author><title>Brain Res.</title></host><title>Muscarinic receptors on dopamine terminals in cat caudate nucleus: neuromodulation of [3H]dopamine release in vitro by endogenous acetylcholine</title></json:item><json:item><author><json:item><name>S. List</name></json:item><json:item><name>P. Seeman</name></json:item></author><host><volume>24</volume><pages><first>1447</first></pages><author></author><title>Life Sci.</title></host><title>Dopamine agonists reverse the elevated [3H]neuroleptic binding in neuroleptic-pretreated rats</title></json:item><json:item><author><json:item><name>K.G. Lloyd</name></json:item><json:item><name>L. Davidson</name></json:item><json:item><name>O. Hornykiewicz</name></json:item></author><host><volume>195</volume><pages><first>453</first></pages><author></author><title>J. Pharmacol. Exp. Ther.</title></host><title>The neurochemistry of Parkinson's disease: effect of L-DOPA therapy</title></json:item><json:item><author><json:item><name>K. Lloyd</name></json:item><json:item><name>H. Mohler</name></json:item><json:item><name>P. Hertz</name></json:item><json:item><name>G. Bartholini</name></json:item></author><host><volume>25</volume><pages><first>789</first></pages><author></author><title>J. Neurochem.</title></host><title>Distribution of choline acetyltransferase and glutamic acid decarboxylase within the substantia nigra and other brain regions from control and parkinsonian patients</title></json:item><json:item><author><json:item><name>O.H. Lowry</name></json:item><json:item><name>N.J. Rosenbrough</name></json:item><json:item><name>A.L. Farr</name></json:item><json:item><name>R.M. Randall</name></json:item></author><host><volume>193</volume><pages><first>265</first></pages><author></author><title>J. Biol. Chem.</title></host><title>Protein measurement with the Folin phenol reagent</title></json:item><json:item><author><json:item><name>P.L. McGeer</name></json:item><json:item><name>E.G. McGeer</name></json:item><json:item><name>V.T. Innanen</name></json:item></author><host><volume>169</volume><pages><first>433</first></pages><author></author><title>Brain Res.</title></host><title>Dendroaxonic transmission. I. Evidence from receptor binding of dopaminergic and cholinergic agents</title></json:item><json:item><author><json:item><name>J.L. Nagy</name></json:item><json:item><name>T. Lee</name></json:item><json:item><name>P. Seeman</name></json:item><json:item><name>H.C. Fibiger</name></json:item></author><host><volume>274</volume><pages><first>278</first></pages><author></author><title>Nature</title></host><title>Direct evidence for pre-synaptic and post-synaptic dopamine receptors in brain</title></json:item><json:item><host><pages><first>355</first></pages><author></author><title>Dissociation between the presynaptic dopamine sensitive adenylate cyclase and [3H]spiperone binding sites in rat substantia nigra 167</title></host></json:item><json:item><author><json:item><name>M. Quik</name></json:item><json:item><name>E.G. Spokes</name></json:item><json:item><name>A.V.P. MacKay</name></json:item><json:item><name>R. Bannister</name></json:item></author><host><volume>43</volume><pages><first>429</first></pages><author></author><title>J. Neurol. Sci.</title></host><title>Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in Shy-Drager syndrome and Parkinson's disease</title></json:item><json:item><author><json:item><name>T.D. Reisine</name></json:item><json:item><name>J.Z. Fields</name></json:item><json:item><name>L.Z. Stern</name></json:item><json:item><name>P.C. Johnson</name></json:item><json:item><name>E.D. Bird</name></json:item><json:item><name>E. Spokes</name></json:item><json:item><name>P.S. Schreiner</name></json:item><json:item><name>S.J. Enna</name></json:item></author><host><volume>21</volume><pages><first>335</first></pages><author></author><title>Life Sci.</title></host><title>Neurotransmitter receptor alterations in Parkinson's disease</title></json:item><json:item><author><json:item><name>T.D. Reisine</name></json:item><json:item><name>J.I. Nagy</name></json:item><json:item><name>H.C. Fibiger</name></json:item><json:item><name>H.I. Yamamura</name></json:item></author><host><volume>169</volume><pages><first>209</first></pages><author></author><title>Brain Res.</title></host><title>Localization of dopamine receptors in rat brain</title></json:item><json:item><author><json:item><name>U.K. Rinne</name></json:item><json:item><name>V. Koskinen</name></json:item><json:item><name>P. Lonnberg</name></json:item></author><host><pages><first>93</first></pages><author></author><title>Parkinson's Disease — Current Progress, Problems and Management</title></host><title>Neurotransmitter receptors in the Parkinsonian brain</title></json:item><json:item><author><json:item><name>U.K. Rinne</name></json:item><json:item><name>V. Sonninen</name></json:item><json:item><name>H. Laaksonen</name></json:item></author><host><author></author><title>Advances in Neurology</title></host><serie><author></author><title>The Extrapyramidal System and its Disorders</title></serie><title>Responses of brain neurochemistry to levodopa treatment in Parkinson's disease</title></json:item><json:item><author><json:item><name>M. Ruberg</name></json:item><json:item><name>A. Ploska</name></json:item><json:item><name>F. Javoy-Agid</name></json:item><json:item><name>Y. Agid</name></json:item></author><host><volume>232</volume><pages><first>129</first></pages><author></author><title>Brain Res.</title></host><title>Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia</title></json:item><json:item><author><json:item><name>B. Scatton</name></json:item></author><host><volume>220</volume><pages><first>197</first></pages><author></author><title>J. Pharmacol. Exp. Ther.</title></host><title>Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity</title></json:item><json:item><author><json:item><name>B. Scatton</name></json:item><json:item><name>F. Javoy-Agid</name></json:item><json:item><name>L. Rouquier</name></json:item><json:item><name>B. Dubois</name></json:item><json:item><name>Y. Agid</name></json:item></author><host><volume>275</volume><pages><first>321</first></pages><author></author><title>Brain Res.</title></host><title>Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease</title></json:item><json:item><author><json:item><name>J.C. Steele</name></json:item><json:item><name>J.C. Richardson</name></json:item><json:item><name>J. Olzsewski</name></json:item></author><host><volume>10</volume><pages><first>333</first></pages><author></author><title>Arch. Neurol.</title></host><title>Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudo-bulbar palsy, nuchal dystonia and dementia</title></json:item></refBibs><genre><json:string>research-article</json:string></genre><serie><editor><json:item><name>L.J. Poirier</name></json:item><json:item><name>T.L. Sourkes</name></json:item><json:item><name>P.J. Bedard</name></json:item></editor><pages><first>259</first></pages><language><json:string>unknown</json:string></language><title>The Extrapyramidal System and its Disorders</title></serie><host><volume>99</volume><pii><json:string>S0014-2999(00)X0450-5</json:string></pii><pages><last>175</last><first>167</first></pages><issn><json:string>0014-2999</json:string></issn><issue>2–3</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><title>European Journal of Pharmacology</title><publicationDate>1984</publicationDate></host><publicationDate>1984</publicationDate><copyrightDate>1984</copyrightDate><doi><json:string>10.1016/0014-2999(84)90238-3</json:string></doi><id>725D196A3549D7EF909C41B41560C57B14E8C280</id><score>0.13975364</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/725D196A3549D7EF909C41B41560C57B14E8C280/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/725D196A3549D7EF909C41B41560C57B14E8C280/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/725D196A3549D7EF909C41B41560C57B14E8C280/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1984</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</title><author xml:id="author-1"><persName><forename type="first">Belinda</forename><surname>Bokobza</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Merle</forename><surname>Ruberg</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Bernard</forename><surname>Scatton</surname></persName><affiliation>Synthélabo-LERS, Départements de Biologie, 31 Av P. Vaillant-Couturier, 92220 Bagneux, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">France</forename><surname>Javoy-Agid</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation><affiliation>To whom all correspondence should be addressed.</affiliation></author><author xml:id="author-5"><persName><forename type="first">Yves</forename><surname>Agid</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation></author></analytic><monogr><title level="j">European Journal of Pharmacology</title><title level="j" type="abbrev">EJP</title><idno type="pISSN">0014-2999</idno><idno type="PII">S0014-2999(00)X0450-5</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1984"></date><biblScope unit="volume">99</biblScope><biblScope unit="issue">2–3</biblScope><biblScope unit="page" from="167">167</biblScope><biblScope unit="page" to="175">175</biblScope></imprint></monogr><idno type="istex">725D196A3549D7EF909C41B41560C57B14E8C280</idno><idno type="DOI">10.1016/0014-2999(84)90238-3</idno><idno type="PII">0014-2999(84)90238-3</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1984</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The density of D2-type dopamine receptors, measured by the binding of [3H]spiperone was normal in the substantia nigra, caudate nucleus and nucleus accumbens of Parkinsonian subjects and above control levels in the putamen, in spite of massive lesions of the dopaminergic neurons. Dopamine levels were reduced in the putamen, caudate nucleus, and nucleus accumbens by 97, 85 and 68%, respectively and by 78 and 93% in the pars compacta and pars reticulata of the substantia nigra. HVA levels were much less affected suggesting that increased activity remaining dopaminergic neurons compensated to some extent for the lesions. Neuroleptic treatment and the presence of dementia in the Parkinsonian subjects affected [3H]spiperone binding and dopamine concentrations. Dopamine and HVA levels in the striatum of subjects with supranuclear palsy indicate that the nigrostriatal system was lesioned to the same degree in this disease as in idiopathic Parkinsonism, but spiperone binding was reduced by half in all the structures studies.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinsonism</term></item><item><term>Supranuclear palsy</term></item><item><term>Dopamine receptor</term></item><item><term>Dopamine</term></item><item><term>Homovanillic acid</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1983-10-20">Modified</change><change when="1984">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/725D196A3549D7EF909C41B41560C57B14E8C280/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>EJP</jid><aid>84902383</aid><ce:pii>0014-2999(84)90238-3</ce:pii><ce:doi>10.1016/0014-2999(84)90238-3</ce:doi><ce:copyright type="unknown" year="1984"></ce:copyright></item-info><head><ce:title>[<ce:sup loc="pre">3</ce:sup>H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</ce:title><ce:author-group><ce:author><ce:given-name>Belinda</ce:given-name><ce:surname>Bokobza</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Merle</ce:given-name><ce:surname>Ruberg</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Bernard</ce:given-name><ce:surname>Scatton</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>∗∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>France</ce:given-name><ce:surname>Javoy-Agid</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="COR1"><ce:sup>‡</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Yves</ce:given-name><ce:surname>Agid</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>∗</ce:label><ce:textfn>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>∗∗</ce:label><ce:textfn>Synthélabo-LERS, Départements de Biologie, 31 Av P. Vaillant-Couturier, 92220 Bagneux, France</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>‡</ce:label><ce:text>To whom all correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="22" month="7" year="1983"></ce:date-received><ce:date-revised day="20" month="10" year="1983"></ce:date-revised><ce:date-accepted day="8" month="11" year="1983"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>The density of D2-type dopamine receptors, measured by the binding of [<ce:sup loc="pre">3</ce:sup>H]spiperone was normal in the substantia nigra, caudate nucleus and nucleus accumbens of Parkinsonian subjects and above control levels in the putamen, in spite of massive lesions of the dopaminergic neurons. Dopamine levels were reduced in the putamen, caudate nucleus, and nucleus accumbens by 97, 85 and 68%, respectively and by 78 and 93% in the pars compacta and pars reticulata of the substantia nigra. HVA levels were much less affected suggesting that increased activity remaining dopaminergic neurons compensated to some extent for the lesions. Neuroleptic treatment and the presence of dementia in the Parkinsonian subjects affected [<ce:sup loc="pre">3</ce:sup>H]spiperone binding and dopamine concentrations. Dopamine and HVA levels in the striatum of subjects with supranuclear palsy indicate that the nigrostriatal system was lesioned to the same degree in this disease as in idiopathic Parkinsonism, but spiperone binding was reduced by half in all the structures studies.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Parkinsonism</ce:text></ce:keyword><ce:keyword><ce:text>Supranuclear palsy</ce:text></ce:keyword><ce:keyword><ce:text>Dopamine receptor</ce:text></ce:keyword><ce:keyword><ce:text>Dopamine</ce:text></ce:keyword><ce:keyword><ce:text>Homovanillic acid</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>[</title></titleInfo><name type="personal"><namePart type="given">Belinda</namePart><namePart type="family">Bokobza</namePart><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Merle</namePart><namePart type="family">Ruberg</namePart><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Scatton</namePart><affiliation>Synthélabo-LERS, Départements de Biologie, 31 Av P. Vaillant-Couturier, 92220 Bagneux, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">France</namePart><namePart type="family">Javoy-Agid</namePart><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation><affiliation>To whom all correspondence should be addressed.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yves</namePart><namePart type="family">Agid</namePart><affiliation>Laboratoire de Médecine Expérimentale, Ecole de Médecine Pitié-Salpêtrière, 91 Bd de l'Hopital, 75634 Paris Cedex 13, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1984</dateIssued><dateModified encoding="w3cdtf">1983-10-20</dateModified><copyrightDate encoding="w3cdtf">1984</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">The density of D2-type dopamine receptors, measured by the binding of [3H]spiperone was normal in the substantia nigra, caudate nucleus and nucleus accumbens of Parkinsonian subjects and above control levels in the putamen, in spite of massive lesions of the dopaminergic neurons. Dopamine levels were reduced in the putamen, caudate nucleus, and nucleus accumbens by 97, 85 and 68%, respectively and by 78 and 93% in the pars compacta and pars reticulata of the substantia nigra. HVA levels were much less affected suggesting that increased activity remaining dopaminergic neurons compensated to some extent for the lesions. Neuroleptic treatment and the presence of dementia in the Parkinsonian subjects affected [3H]spiperone binding and dopamine concentrations. Dopamine and HVA levels in the striatum of subjects with supranuclear palsy indicate that the nigrostriatal system was lesioned to the same degree in this disease as in idiopathic Parkinsonism, but spiperone binding was reduced by half in all the structures studies.</abstract><subject><genre>Keywords</genre><topic>Parkinsonism</topic><topic>Supranuclear palsy</topic><topic>Dopamine receptor</topic><topic>Dopamine</topic><topic>Homovanillic acid</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Pharmacology</title></titleInfo><titleInfo type="abbreviated"><title>EJP</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19840323</dateIssued></originInfo><identifier type="ISSN">0014-2999</identifier><identifier type="PII">S0014-2999(00)X0450-5</identifier><part><date>19840323</date><detail type="volume"><number>99</number><caption>vol.</caption></detail><detail type="issue"><number>2–3</number><caption>no.</caption></detail><extent unit="issue pages"><start>141</start><end>250</end></extent><extent unit="pages"><start>167</start><end>175</end></extent></part></relatedItem><identifier type="istex">725D196A3549D7EF909C41B41560C57B14E8C280</identifier><identifier type="DOI">10.1016/0014-2999(84)90238-3</identifier><identifier type="PII">0014-2999(84)90238-3</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001259 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001259 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:725D196A3549D7EF909C41B41560C57B14E8C280
|texte= [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
}}
| This area was generated with Dilib version V0.6.29. |  |